Dr. Peter S. Kim, Ph.D., is no longer Executive Vice President, President Merck Research Laboratories of Merck & Co., Inc., effective April 15, 2013. He is responsible for the Company?s research and development efforts worldwide. Since January 2008 ? Executive Vice President and President, Merck Research Laboratories, Merck & Co., Inc. ? responsible for the Company?s research and development efforts worldwide. Since January 2003 ? President, Merck Research Laboratories, Merck & Co., Inc. ? responsible for the Company?s research and development efforts worldwide.
Executive VP and President of Merck Research Laboratories
Age: 53 President Since 2009 Ph.D
The company has Return on Asset of 6.32 % which means that on every $100 spent on asset it made $6.32 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.21 % implying that it generated $11.21 on every 100 dollars invested.
The company has 20.57 B in debt with debt to equity (D/E) ratio of 0.37 which is OK given its current industry classification. Merck Co Inc has Current Ratio of 1.86 which is typical for the industry and considered as normal.
Entity SummaryMerck & Co., Inc. offer various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care solutions worldwide. Merck Co Inc [MRK] is traded on New York Stock Exchange in USA. It is located in Whitehouse Station, NJ and employs 82,000 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| MRK NYSE
Merck Co Inc
Merck Co Inc has less than 16.16 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Merck price boundaries
Promote Merck and Peter Kim